Supernus Pharmaceuticals Inc header image

Supernus Pharmaceuticals Inc

SUPN

Equity

ISIN null / Valor 18393960

NASDAQ (2026-11-03)
USD 28.15-32.8%

Supernus Pharmaceuticals Inc
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

Supernus Pharmaceuticals is a U.S.-based specialty pharmaceutical company (NASDAQ: SUPN) that researches, develops, licenses and commercializes branded prescription therapies for central nervous system disorders, particularly in neurology and psychiatry. Its commercial portfolio has included extended‑release antiseizure medicines and, more recently, Qelbree (viloxazine), a non‑stimulant treatment for attention‑deficit/hyperactivity disorder; the company also pursues development-stage candidates, formulation technologies and in‑licensing or partnership arrangements to expand its pipeline and product reach. Supernus generates revenue primarily from sales of its marketed products in the U.S. and from collaboration agreements, while investing in clinical programs aimed at expanding indications and developing new CNS therapies.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

-49.5%1Y
15.0%3Y
-6.26%5Y

Performance

37.4%1Y
36.4%3Y
35.4%5Y

Volatility

Market cap

1636 M

Market cap (USD)

Daily traded volume (Shares)

7,446,175

Daily traded volume (Shares)

1 day high/low

37.28 / 36.11

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Biogen Inc
Biogen Inc Biogen Inc Valor: 1720684
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.81%USD 248.35
Zydus Lifesciences Limited
Zydus Lifesciences Limited Zydus Lifesciences Limited Valor: 29835501
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.12%INR 1,195.00
IPCA Laboratories Limited
IPCA Laboratories Limited IPCA Laboratories Limited Valor: 115718957
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.35%INR 1,942.95
AnaptysBio, Inc.
AnaptysBio, Inc. AnaptysBio, Inc. Valor: 29675116
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.91%USD 46.45
LeMaitre Vascular inc
LeMaitre Vascular inc LeMaitre Vascular inc Valor: 2755054
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-3.11%USD 80.89
GSK PLC
GSK PLC GSK PLC Valor: 120042705
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.16%USD 50.33
Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Limited Valor: 3195888
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
4.32%INR 2,592.85
GSK PLC
GSK PLC GSK PLC Valor: 119642297
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.00%GBP 18.90
Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC Hikma Pharmaceuticals PLC Valor: 2324471
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.77%GBP 16.50
Piramal Pharma Limited
Piramal Pharma Limited Piramal Pharma Limited Valor: 114197705
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.17%INR 239.20